Health · Medical Research · 2 hrs ago
Roche to present new data on Alzheimer’s research
Roche plans to present new Alzheimer’s research data at the CTAD conference, which runs from November 16 to 19, 2026.
One focus is trontinemab, an experimental drug designed to remove amyloid, a protein that builds up in the brain.
Roche will share updated results from an ongoing early-stage study, including how quickly the drug reduces amyloid and how disease markers change.
The company has also begun a phase III trial of trontinemab in people with biological signs of Alzheimer’s but no obvious memory problems.
A second experimental drug, oral RG6434, will be tested in a phase II study in people with early symptoms to see whether blocking a brain inflammation process could help.
The two drugs target different processes, but further trials must show whether either can slow or prevent Alzheimer’s.
Roche will also present data on blood tests used to assess Alzheimer’s-related biology.
Roche plans to present new data on its Alzheimer’s research programmes at the CTAD international Alzheimer’s congress.
The data will include updated results from an ongoing early-stage study of trontinemab, which is designed to remove amyloid deposits in the brain.
Roche has also begun enrolling participants in a Phase III study testing trontinemab in people with biological signs of Alzheimer’s but no noticeable memory problems.
A separate Phase II study will investigate RG6434, an experimental oral drug intended to target inflammation in the brain.
Roche will also present clinical and health-economic data on two blood tests for Alzheimer’s biomarkers.
- Who
- Roche.
- What
- It plans to present new data on its Alzheimer’s research programmes, including drug studies and blood tests.
- When
- At the CTAD congress, scheduled for 16 to 19 November 2026.
- Where
- Not stated.
- Why
- To share research findings on approaches to treating Alzheimer’s and diagnosing its biological signs.
This story does not have two clearly opposing sides.
Roche said it would present updated results from the ongoing Brainshuttle AD study.
Roche had begun enrolling participants in the Phase III Preventron study.
The CTAD international Alzheimer’s congress is scheduled to take place.
- Trontinemab study
- Brainshuttle AD, an ongoing Phase Ib/IIa study
- Preventron
- Phase III study; enrolment has begun
- RG6434 study
- TARBELA-AD, a new Phase II study
- CTAD congress
- 16–19 November 2026
- Blood tests
- Elecsys pTau217 and Elecsys pTau181
What people are saying
Die Beseitigung von Amyloid bleibt eine wichtige Grundlage
Um jedoch eine so komplexe Erkrankung wie Alzheimer aufzuhalten, seien vielfältige und sich ergänzende Therapieansätze erforderlich.